Early Phase 1 Hypertension Trial, Recruiting NCT04546126 Sponsor: Benjamin Viglianti Condition: Hypertension
Back to Hypertension

Early Phase 1 Hypertension Trial, Recruiting

NCT04546126
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Groups 2 & 3 (Healthy Controls):

  • People who have no known problems or conditions affecting their adrenal glands, who would participate as healthy comparison participants during hormone-related testing

Group 4:

  • People who have been found to have abnormal hormone production from the outer layer of their adrenal glands

Who may not be able to join:

Groups 2 & 3:

  • People who are currently pregnant
  • People who are unable to undergo medical imaging scans
  • People who weigh more than 400 pounds (181 kg)
  • People who are currently incarcerated
  • People who are not able to provide their own consent to participate
  • People who are currently taking steroids, the contraceptive pill, spironolactone, estrogen, androgen, progesterone, ACE inhibitors, ARBs (a type of blood pressure medication), or any supplements that act like hormones in the body
  • People who have a known condition affecting their adrenal glands

Group 4:

  • People who are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Benjamin L Viglianti, M.D, Ph.D., University of Michigan

Phone: 734-615-7391

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Benjamin Viglianti
Registry
ClinicalTrials.gov
Start date
1 November 2021
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in [18F]FNP-59 chemistry uptake as measured by the standardized uptake value (SUV) based gland segmentation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov